Journal article
Therapeutic efficacy of177Lu-CHX-A″-DTPA-hu3SI93 radioimmunotherapy in prostate cancer Is enhanced by EGFR inhibition or docetaxel chemotherapy
MP Kelly, ST Lee, FT Lee, FE Smyth, ID Davis, MW Brechbiel, AM Scott
Prostate | Published : 2009
DOI: 10.1002/pros.20856
Abstract
This study investigated the biodistribution and therapeutic efficacy of Lutetium-177 (177Lu) radiolabeled anti-Lewis Y monoclonal antibody hu3S193 radioimmunotherapy (RIT) in mice bearing prostate cancer xenografts. The ability of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor AG1478 and docetaxel chemotherapy to enhance the efficacy of RIT was also assessed in vivo. METHODS. The in vitro cytotoxicity of 177Lu labeled hu3S193 on Ley positive DU145 prostate cancer cells was assessed using proliferation assays, with induction of apoptosis measured by ELISA. The in vivo biodistribution and tumor localization of 177Lu-hu3S193 was assessed in mice bearing established DU145 tumo..
View full abstractGrants
Awarded by National Cancer Institute
Funding Acknowledgements
We thank the staff from the Department of Nuclear Medicine, Austin Hospital, for their assistance in the CT scanning and gamma camera imaging of animals and staff of the Tumour Targeting Program for assistance in biodistribution studies. This work was supported in part by an NH&MRC Program Grant No. 280912 and the Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research. MPK was supported by a Melbourne Research Scholarship, University of Melbourne, Melbourne, Australia. IDD is supported in part by a Victorian Cancer Agency Clinician Researcher Fellowship. MWB is supported by the Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research.